TB-500 (thymosin beta-4)

01Key questions

02Overview

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide that is one of the most abundant peptides in the human body. Tβ4 accounts for ~70–80% of total β-thymosin in humans, is present in virtually all cells (except red blood cells), and plays a fundamental role in actin regulation — the protein responsible for cell shape, movement, and division.

The Tβ4 molecule is functionally partitioned into discrete active fragments (Xing et al., Front Endocrinol 2021, PMID 34992578): - aa 1–4: anti-inflammatory and anti-fibrotic activity - aa 1–15: anti-apoptotic / cell-survival effects - aa 17–23 (LKKTET motif): principal actin-binding domain; drives angiogenesis and hair-follicle growth — this is the minimal "TB-500 fragment" commonly referenced in research contexts.

Regulatory note: Full-length Tβ4 is the molecule investigated in the RegeneRx clinical program and the 2025–26 cardiac RCT. TB-500 (the synthetic 17–23 or active-region analogue) has no comparable human trial program as of mid-2026 (McGuire et al., Appl Sci 2026, DOI 10.3390/app16126202).

Evidence Level: Moderate — Phase II/III human trials in dry eye and dermal wounds; Phase II cardiac RCT ongoing. Extensive preclinical data.

03Mechanism of Action

Primary: Actin Regulation

• G-actin sequestration — Binds globular actin (G-actin) at 1:1 stoichiometry, preventing polymerization into F-actin filaments (Hannappel & Horecker; classical)
• The LKKTET motif (aa 17–23) is the main electrostatic contact site with actin; the C-terminus binds actin His-40, shifting monomer conformation
• Regulates cell motility and cell shape — essential for wound healing and tissue repair
• Profilin-dependent dissociation of the G-actin–Tβ4 complex liberates actin for filament assembly when polymerization is needed

Signaling Pathways

• Integrin-linked kinase (ILK) activation → promotes cardiac cell migration, survival, and repair (Bock-Marquette et al., Nature 2004, PMC3548046)
• Akt2 / PKB pathway — downstream of ILK in lamellipodia; increases metalloproteinase production
• PKC (Protein Kinase C) activation — initiates embryonic coronary developmental program and epicardial progenitor cell activation
• VEGF and angiopoietin-1 / vWF upregulation — promotes angiogenesis via paracrine and endothelial-progenitor recruitment (Xing 2021, PMID 34992578)
• Heat-shock protein 70 (HSP70) elevation — linked to F-actin regulation during burn-wound healing

Additional Pathways (Srinivasan 2025 — Discov Biotechnol, comprehensive review of Tβ4 in diabetic ulcers, DOI 10.1007/s44340-025-00015-0)

• NF-κB suppression — Tβ4 prevents NF-κB nuclear translocation, reducing IL-8, TNF-α, IL-6; first-four-aa fragment is the principal anti-inflammatory determinant
• Nrf2 antioxidant axis — Tβ4 upregulates superoxide dismutase (SOD) and catalase via Nrf2; suppresses NADPH-oxidase-driven ROS — distinct from canonical G-actin role
• Angiopoietin-1 / Tie-2 — Tβ4 increases Ang-1, reduces VCAM-1; restores intraepidermal nerve-fiber density in diabetic neuropathy models
• Wnt/β-catenin — stabilizes β-catenin, promotes nuclear translocation, drives VEGF + keratinocyte/fibroblast ECM remodelling
• PI3K/Akt → eNOS — Tβ4 phosphorylates PI3K/Akt → endothelial nitric oxide synthase → vasodilation + blood-flow to healing tissue; also modulates autophagy via downstream mTOR inhibition
• miR-146a / TLR4 — Tβ4 induces miR-146a in oligodendrocyte precursors (targeting IRAK1, TRAF6), promoting myelin basic protein expression; concurrently activates IκBα to block TLR4-driven inflammation
• High-glucose protection — in HUVECs under hyperglycemia, Tβ4 pretreatment reduces ROS, restores VEGF expression, activates IGF-1 signaling cascade (Wang et al. Discov Biotechnol 2025)
• Lipid metabolism — Tβ4 lowers total cholesterol, triglycerides, LDL-C, raises HDL-C; lowers IL-2/IL-6/TNF-α; protects hepatocytes from palmitic-acid apoptosis via ferroptosis-gene regulation
• Autophagy / DAPK1 — in chronic granulomatous disease (CGD) macrophages, Tβ4 restores autophagy and DAPK1 expression, enhancing phagocytosis against Aspergillus spp.

Downstream Effects

1. Cellular migration — Enhanced movement of keratinocytes, endothelial cells, EPCs to injury sites
2. Angiogenesis — Capillary formation, endothelial tube formation, EPC recruitment (often via VEGF-independent cytoskeletal route distinct from BPC-157/VEGFR2 mechanism)
3. Anti-inflammatory — Reduces inflammatory cytokines; first-four-aa fragment is the principal anti-inflammatory determinant
4. Anti-fibrotic — Reduces scar tissue formation
5. Anti-apoptotic — aa 1–15 segment reduces cytotoxicity
6. Myoblast migration — Muscle stem cell recruitment to injury sites
7. Neuromuscular junction regeneration
8. Laminin-332 synthesis ↑ — migration factor for keratinocytes and endothelial cells

04Primary Uses & Applications

Swipe table →

05Clinical Evidence

Human Clinical Trials

• Dry-eye disease (Phase II/III, RGN-259): Tβ4 ophthalmic solution reduced ocular discomfort, lowered conjunctival inflammation, improved tear-film metrics. Phase I safety studies in healthy volunteers well-tolerated even at higher doses with no dose-limiting toxicities.
• Wound healing (Phase II dermal): Accelerates wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. Conclusions from pooled Phase II data: Tβ4 is safe, well-tolerated, with additional application to skin regeneration (PMC8228050).
• Cardiac repair — STEMI pilot (Phase II, 2016): Tβ4-primed endothelial progenitor cell (EPC) transplantation — pilot suggested feasibility and safety in patients with ST-elevation MI.
• Cardiac RCT (2025–26): New Phase II human data reports measurable ejection-fraction improvement in post-MI recovery; Phase 2b extension registered with longer follow-up, multi-center replication underway.
• Dose-response stroke study (PMC4177939): Tβ4 significantly improved long-term neurological functional recovery at day 56 after MCAo; optimal dose 3.75 mg/kg in rodent model.
• NL005 — first-in-human Phase I SAD/MAD in healthy Chinese volunteers (Wang X, Liu L, Qi L et al. 2021): Recombinant human Tβ4 (Beijing Northland Biotech) evaluated in single-ascending-dose and multiple-ascending-dose arms. Adverse events were mild-to-moderate with no serious toxicities; plasma concentrations increased proportionally with dose (predictable linear PK). Establishes the most rigorous contemporary human safety/PK baseline for full-length rhTβ4. J Cell Mol Med 25(17):8222–8228. DOI 10.1111/jcmm.16693 — cited in Srinivasan 2025 (DOI 10.1007/s44340-025-00015-0).
• Venous stasis ulcer — topical Tβ4 (RegeneRx Phase II): 0.03% concentration was the optimal dose — highest healing rate and significantly reduced median healing time vs. placebo and other doses; larger baseline ulcers had lower healing rates. Cited in Srinivasan 2025.

Key Preclinical Studies

• Bock-Marquette I. et al. (2004). "Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature 432:466–472. PMC3548046.
• Smart N. et al. (2007). "Thymosin beta-4 Is Essential for Coronary Vessel Development and Promotes Neovascularization via Adult Epicardium." Ann N.Y. Acad. Sci. 1112:171–188. PMID 17632766.
• Smart N. et al. (2012). "De novo cardiomyocytes from within the activated adult epicardium." Dev Cell.
• Peng H. et al. (2014). "Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction." Am J Physiol 307:H741–H751.
• Goldstein AL, Hannappel E, Kleinman HK. (2005). "Thymosin β4: Actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med.
• Xing Y, Ye Y, Zuo H, Li Y. (2021). "Progress on the Function and Application of Thymosin β4." Front Endocrinol 12:767785. PMID 34992578 — fragment-function mapping; EPC + VEGF mechanism; fibrosis and oncogenesis review.
• Srinivasan K, Sureshkumar R, Nellore J et al. (2025). "The combined impact of thymosin beta 4 and selenium on diabetic ulcers: a comprehensive review." Discov Biotechnol 2:11. DOI 10.1007/s44340-025-00015-0 — combines Tβ4 mechanisms with selenium antioxidant/anti-inflammatory activity.
• McGuire F, Hughes E, Maak T, Cushman DM. (2026). "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review." Appl Sci 16(12):6202. DOI 10.3390/app16126202 — 80-study scoping review with explicit TB4 vs TB-500 delineation; mechanism/outcome taxonomy (cell migration 12.5%, angiogenesis 23.8%, functional outcomes largely preclinical).
• Stadelmann N. et al. (2025). "Growth Factors IGF-1 and KGF and Adipose-Derived Stem Cells Promote Migration and Viability of Primary Human Keratinocytes in an In Vitro Wound Model." Front Med 12:1516116.
• Hao Q. et al. (2018). "A dimeric thymosin beta 4 with novel bio-activity protects…" — engineered Tβ4 variants.

06Recent Developments (2024–2026)

Swipe table →

07Uses

⚠️ Disclaimer: Research protocols, not medical recommendations.

Swipe table →

08Safety Profile

Swipe table →

09Source & Origin

• Natural source: Present in virtually all mammalian cells; first isolated from thymus gland
• Discovery: Tβ4 identified in the early 1980s by Hannappel E. and Horecker BL
• Key researchers: Alpha and beta thymosins first characterized at the Roche Institute of Molecular Biology (Goldstein, White)
• Clinical development: RegeneRx Biopharmaceuticals (RGN-352 for cardiac; RGN-259 for ophthalmic)

10Diabetic Ulcer & Tβ4 + Selenium Synergy (Srinivasan 2025)

The 2025 review by Srinivasan et al. (DOI 10.1007/s44340-025-00015-0) consolidates evidence for combined Tβ4 + selenium in diabetic ulcer management — a major unmet need (15–30% of diabetics develop ulcers; mortality 40–80% within 6 years post-amputation).

Why synergy is plausible (mechanistic integration)

Swipe table →

Benchmarks from the review (animal/preclinical unless noted)

• SeNPs + PRP (Karas 2024, Sci Rep): SeNPs + platelet-rich plasma in diabetic mice — additive wound healing activity
• Selenium-chitosan-mupirocin nanohybrid: >90% antibacterial, 35–50% faster wound closure in 10 days, ~80% wound-size reduction
• SeNPs-decorated bacterial cellulose/gelatin hydrogel: >95% antibacterial, ~60% ↓ oxidative-stress markers, 40–60% ↑ cell proliferation
• Selenium-stimulated exosomes: 2–3× ↑ VEGF, 30% reduction in healing time, 50% ↓ TNF-α/IL-6
• Fungal-extract SeNPs: 30–40% faster closure, ~80% wound-size reduction by day 10, >90% antibacterial against E. coli/S. aureus
• SeNPs + T2DM metabolic effects: 15–25% ↑ insulin sensitivity, 30–40% ↓ oxidative stress, 20% ↓ triglycerides
• SeNPs in pregnancy (rat model): 30–50% ↓ serum creatinine, 40–60% ↓ oxidative-stress markers in renal tissue

Open questions

• No direct empirical combined-treatment study exists yet — the synergy is theoretical/mechanistic. No Tβ4 + selenium co-administration clinical trial has been registered.
• Optimal Tβ4:Se ratio undefined.
• Selenium toxicity (esp. SeNPs) — narrow therapeutic window.
• Need for delivery systems that maintain stability/bioavailability of both at wound site (scaffolds, hydrogels, nanofibers all proposed).

Adjacent context

Diabetic foot ulcer standard care remains inadequate: hyperbaric O₂ closes ~33% of wounds in 8 weeks; EGF injection → 70–85% closure in 6–8 weeks; adipose MSC exosomes → 40–60% angiogenesis improvement. A combined Tβ4 + selenium strategy has potential to outperform these — but only controlled trials will tell.

11Peptide Combinations

• TB-500 + BPC-157: Most popular combination for tissue repair — TB-500 drives cellular migration / actin remodeling, BPC-157 drives NO/angiogenic signaling via VEGFR2 (distinct mechanisms)
• TB-500 + BPC-157 + GHK-Cu: "Holy trinity" for wound and tissue healing (migration + signaling + ECM)
• TB-500 / Tβ4 + selenium: Combined angiogenic + antioxidant strategy for diabetic ulcers (Srinivasan 2025)
• Tβ4 + EPC transplantation: Cardiac regeneration protocol investigated in STEMI pilot and 2025 RCT

12Where to get it

What studies and practitioners report

Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.

• Trial 0.1% eye drops · Thymosin beta-4 ophthalmic solution (RGN-259) adults with dry eye, n=72, phase 2 PMID 26056426

Further reading: detailed protocols

• r/Peptides community wiki reddit.com

13Connections

14Sources

1. Xing Y, Ye Y, Zuo H, Li Y. (2021). "Progress on the Function and Application of Thymosin β4." Front Endocrinol 12:767785. PMID 34992578 .PubMed 34992578
2. McGuire F, Hughes E, Maak T, Cushman DM. (2026). "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review." Appl Sci 16(12):6202. DOI 10.3390/app16126202 .DOI 10.3390/app16126202
3. Bock-Marquette I. et al. (2004). Nature 432:466–472. PMC3548046 .PMC3548046
4. DOI 10.1007/s44340-025-00015-0DOI 10.1007/s44340-025-00015-0
5. PubMed 40401023PubMed 40401023
6. PMC8228050PMC8228050
7. Morris DC et al. (2014). "A Dose Response Study of Thymosin β4 for the Treatment of Acute Stroke." PMC4177939 .PMC4177939
8. Smart N. et al. (2007). Ann N.Y. Acad. Sci. 1112:171–188. PMID 17632766 .PubMed 17632766
9. Karas RA, Alexeree S, Elsayed H, Attia YA. (2024). "Assessment of wound healing activity in diabetic mice treated with a novel therapeutic combination of selenium nanoparticles and platelets rich plasma." Sci Rep . DOI 10.1038/s41598-024-54064-2 .DOI 10.1038/s41598-024-54064-2

15Entry history

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.